{'52WeekChange': -0.2889514,
 'SandP52WeekChange': None,
 'address1': '10 Hudson Yards',
 'address2': '37th floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 47,
 'askSize': 900,
 'averageDailyVolume10Day': 964075,
 'averageVolume': 998236,
 'averageVolume10days': 964075,
 'beta': 1.774789,
 'beta3Year': None,
 'bid': 44.5,
 'bidSize': 1200,
 'bookValue': -1.054,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 45.865,
 'dayLow': 43.71,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.866,
 'enterpriseToRevenue': 5.51,
 'enterpriseValue': 1501039488,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 60.85057,
 'fiftyTwoWeekHigh': 125,
 'fiftyTwoWeekLow': 42.19,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 26631889,
 'forwardEps': -9.1,
 'forwardPE': -4.9923077,
 'fromCurrency': None,
 'fullTimeEmployees': 583,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.21515,
 'heldPercentInstitutions': 0.80266,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/interceptpharma.com',
 'longBusinessSummary': 'Intercept Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, focuses on the development and '
                        'commercialization of therapeutics to treat '
                        'progressive non-viral liver diseases in the United '
                        'States, Europe, and Canada. Its lead products '
                        'candidate is the Ocaliva, a farnesoid X receptor '
                        'agonist used for the treatment of primary biliary '
                        'cholangitis (PBC) in combination with ursodeoxycholic '
                        'acid in adults. The company is also developing '
                        'Ocaliva for various indications, including '
                        'nonalcoholic steatohepatitis (NASH); and several '
                        'other product candidates in various stages of '
                        'clinical and preclinical development. It has a '
                        'license agreement with Sumitomo Dainippon Pharma Co. '
                        'Ltd. for the research, development, and '
                        'commercialization of OCA as a therapeutic for the '
                        'treatment of PBC and NASH in Japan and China; and '
                        'Aralez Pharmaceuticals Canada Inc to develop and '
                        'commercialize bezafibrate in the United States. The '
                        'company markets its products through an internal '
                        'commercial organization, a contract sales '
                        'organization, and third-party distributors. Intercept '
                        'Pharmaceuticals, Inc. was founded in 2002 and is '
                        'headquartered in New York, New York.',
 'longName': 'Intercept Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 1496605056,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_11382658',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -347393984,
 'nextFiscalYearEnd': 1640908800,
 'open': 45.11,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.45,
 'phone': '646 747 1000',
 'previousClose': 45.5,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 5.494105,
 'profitMargins': -1.2753,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 45.865,
 'regularMarketDayLow': 43.71,
 'regularMarketOpen': 45.11,
 'regularMarketPreviousClose': 45.5,
 'regularMarketPrice': 45.11,
 'regularMarketVolume': 480741,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 32943100,
 'sharesPercentSharesOut': 0.19479999,
 'sharesShort': 6416540,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5787659,
 'shortName': 'Intercept Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.309,
 'shortRatio': 5.42,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'ICPT',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -10.737,
 'twoHundredDayAverage': 78.20381,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '40f718fb-7eea-3be4-9d1d-c04a98411306',
 'volume': 480741,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.interceptpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10001'}